Acinetobacter baumannii clinical isolates have the ability to survive in the hospital niche for prolonged time periods and to develop resistance against multiple antimicrobial agents. Therefore, A. baumannii has emerged as an important cause of nosocomial outbreaks worldwide, especially in critical-care environments such as intensive care units. In the present communication, we report a multi-drug-resistant A. baumannii outbreak that occurred in an orthopedics department in Greece after the admission of a patient previously hospitalized in the intensive care unit of a Greek tertiary care hospital. Despite the implementation of infection control measures, 29 patients were infected, significantly raising their hospitalization periods and treatment costs. Interestingly, the outbreak was put under control after the department’s previously programmed relocation.
References
[1]
Miyakis, S.; Pefanis, A.; Tsakris, A. The challenges of antimicrobial drug resistance in Greece. Clin. Infect. Dis. 2011, 53, 177–184.
[2]
Pournaras, S.; Markogiannakis, A.; Ikonomidis, A.; Kondyli, L.; Bethimouti, K.; Maniatis, A.N.; Legakis, N.J.; Tsakris, A. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J. Antimicrob. Chemother. 2006, 57, 557–561.
[3]
Poirel, L.; Lebessi, E.; Héritier, C.; Patsoura, A.; Foustoukou, M.; Nordmann, P. Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece. Clin. Microbiol. Infect. 2006, 12, 1138–1141.
[4]
Papa, A.; Koulourida, V.; Souliou, E. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a newly established Greek hospital. Microb. Drug Resist. 2009, 15, 257–260.
Ikonomidis, A.; Ntokou, E.; Maniatis, A.N.; Tsakris, A.; Pournaras, S. Hidden VIM-1 metallo-β-lactamase phenotypes among Acinetobacter baumannii clinical isolates. J. Clin. Microbiol. 2008, 46, 346–349.
[7]
Loli, A.; Tzouvelekis, L.S.; Gianneli, D.; Tzelepi, E.; Miriagou, V. Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests. Antimicrob. Agents Chemother. 2008, 52, 1894–1896.
[8]
Tsakris, A.; Poulou, A.; Pournaras, S.; Voulgari, E.; Vrioni, G.; Themeli-Digalaki, K.; Petropoulou, D.; Sofianou, D. A simple phenotypic method for the differentiation of metallo-β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J. Antimicrob. Chemother. 2010, 65, 1664–1671.
[9]
Diancourt, L.; Passet, V.; Nemec, A.; Dijkshoorn, L.; Brisse, S. The population structure of Acinetobacter baumannii: Expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 2010, 5, e10034.
[10]
Tsakris, A.; Tsioni, C.; Pournaras, S.; Polyzos, S.; Maniatis, A.N.; Sofianou, D. Spread of low-level carbapenem-resistant Acinetobacter baumannii clones in a tertiary care Greek hospital. J. Antimicrob. Chemother. 2003, 52, 1046–1047.
[11]
Gogou, V.; Pournaras, S.; Giannouli, M.; Voulgari, E.; Piperaki, E.T.; Zarrilli, R.; Tsakris, A. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: A 10 year study in Greece (2000–09). J. Antimicrob. Chemother. 2011, 66, 2767–2772.
[12]
Liakopoulos, A.; Miriagou, V.; Katsifas, E.; Karagouni, A.D.; Daikos, G.L.; Tzouvelekis, L.S.; Petinaki, E. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill. 2012, 17, p. 20117. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20117 (accessed on 22 November 2013).
